Detalhe da pesquisa
1.
Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Diabetes Obes Metab
; 25(10): 2999-3011, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37417372
2.
The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
ESC Heart Fail
; 10(2): 943-954, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36479630
3.
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
Am J Cardiovasc Drugs
; 22(5): 535-544, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35353351
4.
Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy.
J Clin Med
; 10(21)2021 Oct 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34768510
5.
Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age.
Future Cardiol
; 17(6): 1131-1142, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33733830
6.
Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients.
J Clin Med
; 8(10)2019 Oct 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31581623